<DOC>
	<DOCNO>NCT01399190</DOCNO>
	<brief_summary>This prospective observational study evaluate efficacy safety bevacizumab combination capecitabine oxaliplatin first-line treatment participant colorectal cancer . Data collect participant disease progression occur ( 30 month ) .</brief_summary>
	<brief_title>An Observational Study Avastin ( Bevacizumab ) Combination With Xeloda ( Capecitabine ) And Oxaliplatin Patients With Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Metastatic colorectal cancer Treatment accordance current Summary Product Characteristics local guideline Contraindications accord current Summary Product Characteristics local guideline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>